LYNC-101
/ LyncBio Therapeutics (Shanghai) Co., Ltd
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 28, 2026
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=50 | Enrolling by invitation | Sponsor: LyncBio Therapeutics Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation
Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
April 02, 2026
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: LyncBio Therapeutics Co., Ltd.
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 2
Of
2
Go to page
1